Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Novak, Petr [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport - Fang, Jun ELSEVIER, 2014transfer abstract, London |
|---|---|
| Übergeordnetes Werk: |
volume:16 ; year:2017 ; number:2 ; pages:123-134 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1474-4422(16)30331-3 |
|---|
| Katalog-ID: |
ELV030300746 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030300746 | ||
| 003 | DE-627 | ||
| 005 | 20230623204438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(16)30331-3 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017004000027.pica |
| 035 | |a (DE-627)ELV030300746 | ||
| 035 | |a (ELSEVIER)S1474-4422(16)30331-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.17 |2 bkl | ||
| 084 | |a 58.50 |2 bkl | ||
| 084 | |a 43.12 |2 bkl | ||
| 100 | 1 | |a Novak, Petr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| 264 | 1 | |c 2017 | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. | ||
| 700 | 1 | |a Schmidt, Reinhold |4 oth | |
| 700 | 1 | |a Kontsekova, Eva |4 oth | |
| 700 | 1 | |a Zilka, Norbert |4 oth | |
| 700 | 1 | |a Kovacech, Branislav |4 oth | |
| 700 | 1 | |a Skrabana, Rostislav |4 oth | |
| 700 | 1 | |a Vince-Kazmerova, Zuzana |4 oth | |
| 700 | 1 | |a Katina, Stanislav |4 oth | |
| 700 | 1 | |a Fialova, Lubica |4 oth | |
| 700 | 1 | |a Prcina, Michal |4 oth | |
| 700 | 1 | |a Parrak, Vojtech |4 oth | |
| 700 | 1 | |a Dal-Bianco, Peter |4 oth | |
| 700 | 1 | |a Brunner, Martin |4 oth | |
| 700 | 1 | |a Staffen, Wolfgang |4 oth | |
| 700 | 1 | |a Rainer, Michael |4 oth | |
| 700 | 1 | |a Ondrus, Matej |4 oth | |
| 700 | 1 | |a Ropele, Stefan |4 oth | |
| 700 | 1 | |a Smisek, Miroslav |4 oth | |
| 700 | 1 | |a Sivak, Roman |4 oth | |
| 700 | 1 | |a Winblad, Bengt |4 oth | |
| 700 | 1 | |a Novak, Michal |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Lancet Publ. Group |a Fang, Jun ELSEVIER |t Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |d 2014transfer abstract |g London |w (DE-627)ELV017537959 |
| 773 | 1 | 8 | |g volume:16 |g year:2017 |g number:2 |g pages:123-134 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1474-4422(16)30331-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 35.17 |j Katalyse |q VZ |
| 936 | b | k | |a 58.50 |j Umwelttechnik: Allgemeines |q VZ |
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 16 |j 2017 |e 2 |h 123-134 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p n pn |
|---|---|
| matchkey_str |
novakpetrschmidtreinholdkontsekovaevazil:2017----:aeynimngnctoteavcieavciptetwtazemrdsaernoiedul |
| hierarchy_sort_str |
2017 |
| bklnumber |
35.17 58.50 43.12 |
| publishDate |
2017 |
| allfields |
10.1016/S1474-4422(16)30331-3 doi GBVA2017004000027.pica (DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Novak, Petr verfasserin aut Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial 2017 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. Schmidt, Reinhold oth Kontsekova, Eva oth Zilka, Norbert oth Kovacech, Branislav oth Skrabana, Rostislav oth Vince-Kazmerova, Zuzana oth Katina, Stanislav oth Fialova, Lubica oth Prcina, Michal oth Parrak, Vojtech oth Dal-Bianco, Peter oth Brunner, Martin oth Staffen, Wolfgang oth Rainer, Michael oth Ondrus, Matej oth Ropele, Stefan oth Smisek, Miroslav oth Sivak, Roman oth Winblad, Bengt oth Novak, Michal oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:16 year:2017 number:2 pages:123-134 extent:12 https://doi.org/10.1016/S1474-4422(16)30331-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 16 2017 2 123-134 12 045F 610 |
| spelling |
10.1016/S1474-4422(16)30331-3 doi GBVA2017004000027.pica (DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Novak, Petr verfasserin aut Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial 2017 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. Schmidt, Reinhold oth Kontsekova, Eva oth Zilka, Norbert oth Kovacech, Branislav oth Skrabana, Rostislav oth Vince-Kazmerova, Zuzana oth Katina, Stanislav oth Fialova, Lubica oth Prcina, Michal oth Parrak, Vojtech oth Dal-Bianco, Peter oth Brunner, Martin oth Staffen, Wolfgang oth Rainer, Michael oth Ondrus, Matej oth Ropele, Stefan oth Smisek, Miroslav oth Sivak, Roman oth Winblad, Bengt oth Novak, Michal oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:16 year:2017 number:2 pages:123-134 extent:12 https://doi.org/10.1016/S1474-4422(16)30331-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 16 2017 2 123-134 12 045F 610 |
| allfields_unstemmed |
10.1016/S1474-4422(16)30331-3 doi GBVA2017004000027.pica (DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Novak, Petr verfasserin aut Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial 2017 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. Schmidt, Reinhold oth Kontsekova, Eva oth Zilka, Norbert oth Kovacech, Branislav oth Skrabana, Rostislav oth Vince-Kazmerova, Zuzana oth Katina, Stanislav oth Fialova, Lubica oth Prcina, Michal oth Parrak, Vojtech oth Dal-Bianco, Peter oth Brunner, Martin oth Staffen, Wolfgang oth Rainer, Michael oth Ondrus, Matej oth Ropele, Stefan oth Smisek, Miroslav oth Sivak, Roman oth Winblad, Bengt oth Novak, Michal oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:16 year:2017 number:2 pages:123-134 extent:12 https://doi.org/10.1016/S1474-4422(16)30331-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 16 2017 2 123-134 12 045F 610 |
| allfieldsGer |
10.1016/S1474-4422(16)30331-3 doi GBVA2017004000027.pica (DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Novak, Petr verfasserin aut Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial 2017 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. Schmidt, Reinhold oth Kontsekova, Eva oth Zilka, Norbert oth Kovacech, Branislav oth Skrabana, Rostislav oth Vince-Kazmerova, Zuzana oth Katina, Stanislav oth Fialova, Lubica oth Prcina, Michal oth Parrak, Vojtech oth Dal-Bianco, Peter oth Brunner, Martin oth Staffen, Wolfgang oth Rainer, Michael oth Ondrus, Matej oth Ropele, Stefan oth Smisek, Miroslav oth Sivak, Roman oth Winblad, Bengt oth Novak, Michal oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:16 year:2017 number:2 pages:123-134 extent:12 https://doi.org/10.1016/S1474-4422(16)30331-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 16 2017 2 123-134 12 045F 610 |
| allfieldsSound |
10.1016/S1474-4422(16)30331-3 doi GBVA2017004000027.pica (DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Novak, Petr verfasserin aut Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial 2017 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. Schmidt, Reinhold oth Kontsekova, Eva oth Zilka, Norbert oth Kovacech, Branislav oth Skrabana, Rostislav oth Vince-Kazmerova, Zuzana oth Katina, Stanislav oth Fialova, Lubica oth Prcina, Michal oth Parrak, Vojtech oth Dal-Bianco, Peter oth Brunner, Martin oth Staffen, Wolfgang oth Rainer, Michael oth Ondrus, Matej oth Ropele, Stefan oth Smisek, Miroslav oth Sivak, Roman oth Winblad, Bengt oth Novak, Michal oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:16 year:2017 number:2 pages:123-134 extent:12 https://doi.org/10.1016/S1474-4422(16)30331-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 16 2017 2 123-134 12 045F 610 |
| language |
English |
| source |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:16 year:2017 number:2 pages:123-134 extent:12 |
| sourceStr |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:16 year:2017 number:2 pages:123-134 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Katalyse Umwelttechnik: Allgemeines Umweltchemie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| authorswithroles_txt_mv |
Novak, Petr @@aut@@ Schmidt, Reinhold @@oth@@ Kontsekova, Eva @@oth@@ Zilka, Norbert @@oth@@ Kovacech, Branislav @@oth@@ Skrabana, Rostislav @@oth@@ Vince-Kazmerova, Zuzana @@oth@@ Katina, Stanislav @@oth@@ Fialova, Lubica @@oth@@ Prcina, Michal @@oth@@ Parrak, Vojtech @@oth@@ Dal-Bianco, Peter @@oth@@ Brunner, Martin @@oth@@ Staffen, Wolfgang @@oth@@ Rainer, Michael @@oth@@ Ondrus, Matej @@oth@@ Ropele, Stefan @@oth@@ Smisek, Miroslav @@oth@@ Sivak, Roman @@oth@@ Winblad, Bengt @@oth@@ Novak, Michal @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV017537959 |
| dewey-sort |
3610 |
| id |
ELV030300746 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030300746</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204438.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(16)30331-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000027.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030300746</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(16)30331-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Novak, Petr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, Reinhold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kontsekova, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zilka, Norbert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kovacech, Branislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skrabana, Rostislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vince-Kazmerova, Zuzana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katina, Stanislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fialova, Lubica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prcina, Michal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parrak, Vojtech</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dal-Bianco, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunner, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Staffen, Wolfgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rainer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ondrus, Matej</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ropele, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smisek, Miroslav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sivak, Roman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winblad, Bengt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Novak, Michal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:123-134</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(16)30331-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">123-134</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Novak, Petr |
| spellingShingle |
Novak, Petr ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| authorStr |
Novak, Petr |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV017537959 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| topic |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_unstemmed |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_browse |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r s rs e k ek n z nz b k bk r s rs z v k zvk s k sk l f lf m p mp v p vp p d b pdb m b mb w s ws m r mr m o mo s r sr m s ms r s rs b w bw m n mn |
| hierarchy_parent_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| hierarchy_parent_id |
ELV017537959 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV017537959 |
| title |
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| ctrlnum |
(DE-627)ELV030300746 (ELSEVIER)S1474-4422(16)30331-3 |
| title_full |
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| author_sort |
Novak, Petr |
| journal |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| journalStr |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
123 |
| author_browse |
Novak, Petr |
| container_volume |
16 |
| physical |
12 |
| class |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Novak, Petr |
| doi_str_mv |
10.1016/S1474-4422(16)30331-3 |
| dewey-full |
610 570 540 |
| title_sort |
safety and immunogenicity of the tau vaccine aadvac1 in patients with alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| title_auth |
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| abstract |
Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. |
| abstractGer |
Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. |
| abstract_unstemmed |
Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 |
| container_issue |
2 |
| title_short |
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial |
| url |
https://doi.org/10.1016/S1474-4422(16)30331-3 |
| remote_bool |
true |
| author2 |
Schmidt, Reinhold Kontsekova, Eva Zilka, Norbert Kovacech, Branislav Skrabana, Rostislav Vince-Kazmerova, Zuzana Katina, Stanislav Fialova, Lubica Prcina, Michal Parrak, Vojtech Dal-Bianco, Peter Brunner, Martin Staffen, Wolfgang Rainer, Michael Ondrus, Matej Ropele, Stefan Smisek, Miroslav Sivak, Roman Winblad, Bengt Novak, Michal |
| author2Str |
Schmidt, Reinhold Kontsekova, Eva Zilka, Norbert Kovacech, Branislav Skrabana, Rostislav Vince-Kazmerova, Zuzana Katina, Stanislav Fialova, Lubica Prcina, Michal Parrak, Vojtech Dal-Bianco, Peter Brunner, Martin Staffen, Wolfgang Rainer, Michael Ondrus, Matej Ropele, Stefan Smisek, Miroslav Sivak, Roman Winblad, Bengt Novak, Michal |
| ppnlink |
ELV017537959 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1474-4422(16)30331-3 |
| up_date |
2024-07-06T17:13:39.010Z |
| _version_ |
1803850632672575488 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030300746</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204438.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(16)30331-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000027.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030300746</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(16)30331-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Novak, Petr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, Reinhold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kontsekova, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zilka, Norbert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kovacech, Branislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skrabana, Rostislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vince-Kazmerova, Zuzana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katina, Stanislav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fialova, Lubica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prcina, Michal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parrak, Vojtech</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dal-Bianco, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunner, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Staffen, Wolfgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rainer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ondrus, Matej</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ropele, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smisek, Miroslav</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sivak, Roman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winblad, Bengt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Novak, Michal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:123-134</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(16)30331-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">123-134</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4025326 |